Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
Status:
NOT_YET_RECRUITING
Trial end date:
2031-06-01
Target enrollment:
Participant gender:
Summary
GIANT is an open-label, multi-center, randomized, perioperative (neoadjuvant followed by adjuvant), phase 2 trial with a safety lead-in phase to investigate the feasibility, safety and tolerability, and establish the biological activity of nivolumab with or without relatlimab in patients with isocitrate dehydrogenase (IDH) wildtype newly diagnosed glioblastoma (ndGBM).